.jpg "Nektar Therapeutics (NASDAQ: NKTR)")
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nektar Therapeutics (NASDAQ: NKTR) and G1 Therapeutics Inc (NASDAQ: GTHX) with bullish sentiments.
Nektar Therapeutics (NASDAQ: NKTR)
H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Nektar Therapeutics (NASDAQ: NKTR) today and set a price target of $97. The company’s shares closed on Friday at $90.35.
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 4.0% and a 50.8% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Voyager Therapeutics Inc.
Currently, the analyst consensus on Nektar Therapeutics is Strong Buy and the average price target is $106.67, representing a 18.1% upside.
In a report issued on May 23, Mizuho Securities also assigned a Buy rating to the stock with a $103 price target.
See today’s analyst top recommended stocks >>
G1 Therapeutics Inc (NASDAQ: GTHX)
H.C. Wainwright analyst Edward White maintained a Buy rating on G1 Therapeutics Inc (NASDAQ: GTHX) today and set a price target of $61. The company’s shares closed on Friday at $43.60.
According to TipRanks.com, White is a 5-star analyst with an average return of 26.7% and a 55.2% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Synthetic Biologics Inc, and Karyopharm Therapeutics.
Currently, the analyst consensus on G1 Therapeutics Inc is Strong Buy and the average price target is $60.33, representing a 38.4% upside.
In a report issued on May 24, BTIG also assigned a Buy rating to the stock with a $60 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
